Breast Recurrence Score Test Market Size

  • Report ID: 5394
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Breast Recurrence Score Test Market Size

Breast Recurrence Score Test Market size is anticipated to reach USD 20 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of breast recurrence score test was over USD 10 Billion. The increasing emphasis on value-based healthcare is one of the main growth drivers fueling the market. The shift towards value-based healthcare is transforming the landscape of medical practices, emphasizing the importance of outcomes that matter most to patients. In the context of breast cancer, where treatment decisions have profound implications for patients' quality of life, value-based healthcare encourages the adoption of diagnostic tools that not only improve clinical outcomes but also contribute to cost-effectiveness and resource optimization. A study published demonstrated that the use of the Oncotype DX Breast Recurrence Score Test led to a significant reduction in chemotherapy use among patients with early-stage, estrogen receptor-positive breast cancer. The study reported a 46.6% reduction in the use of chemotherapy.

The breast recurrence score test is a diagnostic tool used in the field of breast cancer management to assess the risk of recurrence in early-stage, hormone receptor-positive breast cancer patients. This test provides valuable information to help guide treatment decisions, particularly with regard to whether or not to administer chemotherapy in addition to hormonal therapy. The market for breast recurrence score testing includes competition from other genetic tests and platforms aimed at assessing breast cancer prognosis and treatment planning.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5394
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of breast recurrence score test is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Genomic Health, Inc., Agendia, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample